Future developments in the prevention, diagnosis and treatment of COVID-19

2020 Apolone, 2020, Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy, Tumori 2020 Live Science, 2020 WHO, 2020 UK Government, 2020 Emanuel, 2020 Elsaddig, 2021, Effects of the COVID pandemic on pregnancy outcomes, Best Pract Res Clin Obstet Gynaecol, 73, 125, 10.1016/j.bpobgyn.2021.03.004 Jardine, 2021, COVID-19 in Women's Health: Epidemiology, Best Pract Res Clin Obstet Gynaecol, 73, 81, 10.1016/j.bpobgyn.2021.03.010 Knight, 2020, Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study, BMJ, 369, m2107, 10.1136/bmj.m2107 Royal College of Obstetricians and Gynaecologists (RCOG), 2020 Allotey, 2020, Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis, Bmj, 370, m3320, 10.1136/bmj.m3320 Pierce-Williams, 2020, Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies: a United States cohort study, Am J Obstet Gynecol MFM, 2, 100134, 10.1016/j.ajogmf.2020.100134 UK Government, 2021 Department of Health & Social Care (DHSC), 2020 Jones, 2020, Two metres or one: what is the evidence for physical distancing in covid-19?, BMJ, 370, m3223, 10.1136/bmj.m3223 Flügge, 1897, Ueber luftinfection, Z Hyg Infektionskr, 25, 179 Bourouiba, 2020, Turbulent gas clouds and respiratory pathogen emissions: potential implications for reducing transmission of COVID-19, Jama, 323, 1837 Hamburger, 1948, Expulsion of group A hemolytic streptococci in droplets and droplet nuclei by sneezing, coughing and talking, Am J Med, 4, 690, 10.1016/S0002-9343(48)90392-1 Bahl, 2020, Airborne or droplet precautions for health workers treating COVID-19?, J Infect Dis Bourouiba, 2016, Images in clinical medicine. a sneeze, N Engl J Med, 375, e15, 10.1056/NEJMicm1501197 Yu, 2004, Evidence of airborne transmission of the severe acute respiratory syndrome virus, N Engl J Med, 350, 1731, 10.1056/NEJMoa032867 Tang, 2006, Factors involved in the aerosol transmission of infection and control of ventilation in healthcare premises, J Hosp Infect, 64, 100, 10.1016/j.jhin.2006.05.022 2020 Chu, 2020, Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis, Lancet, 395, 1973, 10.1016/S0140-6736(20)31142-9 Feng, 2020, Rational use of face masks in the COVID-19 pandemic, Lancet Resp Med, 8, 434, 10.1016/S2213-2600(20)30134-X WHO, 2020 Royal Society, 2020 WHO, 2020 Greenhalgh, 2020, Face masks for the public during the covid-19 crisis, Bmj, 369, m1435, 10.1136/bmj.m1435 Bartoszko, 2020, Medical masks vs N95 respirators for preventing COVID-19 in healthcare workers: a systematic review and meta-analysis of randomized trials, Influenza Other Respir Viruses, 14, 365, 10.1111/irv.12745 Xiao, 2020, Nonpharmaceutical measures for pandemic influenza in nonhealthcare settings-personal protective and environmental measures, Emerg Infect Dis, 26, 967, 10.3201/eid2605.190994 Jefferson, 2011, Physical interventions to interrupt or reduce the spread of respiratory viruses, Cochrane Database Syst Rev, 2011 Brainard, 2020 Bundgaard, 2020, Effectiveness of adding a mask recommendation to other public health measures to prevent SARS-CoV-2 infection in Danish mask wearers : a randomized controlled trial, Ann Intern Med, 174, 335, 10.7326/M20-6817 Howard, 2021, An evidence review of face masks against COVID-19, Proc Natl Acad Sci Unit States Am, 118, 10.1073/pnas.2014564118 Brooks, 2021, Maximizing fit for cloth and medical procedure masks to improve performance and reduce SARS-CoV-2 transmission and exposure, 70, 254 Kucharski, 2020, Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study, Lancet Infect Dis, 20, 1151, 10.1016/S1473-3099(20)30457-6 Fraser, 2004, Factors that make an infectious disease outbreak controllable, Proc Natl Acad Sci U S A, 101, 6146, 10.1073/pnas.0307506101 Hellewell, 2020, Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts, Lancet Glob Health, 8, e488, 10.1016/S2214-109X(20)30074-7 He, 2020, Temporal dynamics in viral shedding and transmissibility of COVID-19, Nat Med, 26, 672, 10.1038/s41591-020-0869-5 McAloon, 2020, Incubation period of COVID-19: a rapid systematic review and meta-analysis of observational research, BMJ Open, 10, 10.1136/bmjopen-2020-039652 Cevik, 2021, SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis, Lancet Microbe, 2, e13, 10.1016/S2666-5247(20)30172-5 Cevik, 2020, Virology, transmission, and pathogenesis of SARS-CoV-2, BMJ, 371, m3862, 10.1136/bmj.m3862 2021 Sutton, 2020, Universal screening for SARS-CoV-2 in women admitted for delivery, N Engl J Med, 382, 2163, 10.1056/NEJMc2009316 WHO, 2020 Funk, 2020, A snapshot of the global race for vaccines targeting SARS-CoV-2 and the COVID-19 pandemic, Front Pharmacol, 11 WHO, 2020 2020 Akpan, 2020 Ball, 2021, The lightning-fast quest for COVID vaccines - and what it means for other diseases, Nature, 589, 16, 10.1038/d41586-020-03626-1 Noad, 2019, UK vaccines network: mapping priority pathogens of epidemic potential and vaccine pipeline developments, Vaccine, 37, 6241, 10.1016/j.vaccine.2019.09.009 2020 2020 2020 UK Government, 2020 Pardi, 2018, mRNA vaccines - a new era in vaccinology, Nat Rev Drug Discov, 17, 261, 10.1038/nrd.2017.243 PHG Foundation, 2018 Thanh Le, 2020, The COVID-19 vaccine development landscape, Nat Rev Drug Discov, 19, 305, 10.1038/d41573-020-00073-5 2021 Voysey, 2021, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK, Lancet, 397, 99, 10.1016/S0140-6736(20)32661-1 Voysey, 2021, Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials, Lancet, 397, 881, 10.1016/S0140-6736(21)00432-3 2021 Polack, 2020, Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine, N Engl J Med, 383, 2603, 10.1056/NEJMoa2034577 Baden, 2021, Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine, N Engl J Med, 384, 403, 10.1056/NEJMoa2035389 Novavax, 2021 MHRA, 2021 Gong, 2020 DHSC, 2020 2021 2021 2021 2021 MHRA, 2020 MHRA, 2020 MHRA, 2021 MHRA, 2021 UK Chief Medical Officers, 2020 2021 Pfizer, 2020 RCGP, 2021 Royal Pharmaceutical Society, 2021 2021 Horby, 2020, Effect of hydroxychloroquine in hospitalized patients with covid-19, N Engl J Med, 383, 2030, 10.1056/NEJMoa2022926 WHO, 2021 WHO, 2021 PHE, 2021 2021 CureVac, 2021 Böger, 2021, Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19, Am J Infect Contr, 49, 21, 10.1016/j.ajic.2020.07.011 Kucirka, 2020, Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure, Ann Intern Med, 173, 262, 10.7326/M20-1495 Lauer, 2020, The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application, Ann Intern Med, 172, 577, 10.7326/M20-0504 Crozier, 2021, Put to the test: use of rapid testing technologies for covid-19, BMJ, 372, n208, 10.1136/bmj.n208 SAGE, 2020 2020 Deeks, 2020, Antibody tests for identification of current and past infection with SARS-CoV-2, Cochrane Database Syst Rev, 6 Watson, 2020, Testing for SARS-CoV-2 antibodies, BMJ, 370, m3325, 10.1136/bmj.m3325 Zuo, 2021, Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection, Nature Immunology Wise, 2020, Covid-19: T cell response lasts for at least six months after infection, study shows, BMJ, 371, m4257, 10.1136/bmj.m4257 Lennard, 2021 PHE & University of Oxford, 2020 Mina, 2020, Rethinking covid-19 test sensitivity - a strategy for containment, N Engl J Med, 383, 10.1056/NEJMp2025631 Kissler, 2020, Viral dynamics of SARS-CoV-2 infection and the predictive value of repeat testing, medRxiv Corman, 2020, Comparison of seven commercial SARS-CoV-2 rapid Point-of-Care Antigen tests, Lancet Microbe Bullard, 2020, Predicting infectious SARS-CoV-2 from diagnostic samples, Clin Infect Dis, 71, 2663, 10.1093/cid/ciaa638 Larremore, 2020, Test sensitivity is secondary to frequency and turnaround time for COVID-19 surveillance, medRxiv Lanièce Delaunay, 2020, Evaluation of testing frequency and sampling for severe acute respiratory syndrome coronavirus 2 surveillance strategies in long-term care facilities, J Am Med Dir Assoc, 21, 10.1016/j.jamda.2020.08.022 Grassly, 2020, Comparison of molecular testing strategies for COVID-19 control: a mathematical modelling study, Lancet Infect Dis, 20, 1381, 10.1016/S1473-3099(20)30630-7 2020 DHSC, 2020 Peto, 2020, Diagnosis of SARS-CoV-2 infection with LamPORE, a high-throughput platform combining loop-mediated isothermal amplification and nanopore sequencing, medRxiv 2020 2020 Iacobucci, 2020, Operation Moonshot: leaked documents prompt questions over cost, evidence, and reliance on private sector, BMJ, 370, m3580, 10.1136/bmj.m3580 2020 Iacobucci, 2020, Covid-19: government shelves plans to invest £100bn in mass testing, BMJ, 371, m4112, 10.1136/bmj.m4112 Houlihan, 2020, Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers, Lancet, 396, e6, 10.1016/S0140-6736(20)31484-7 Quilty, 2021, Quarantine and testing strategies in contact tracing for SARS-CoV-2, Lancet Public Health, 6, e175, 10.1016/S2468-2667(20)30308-X WHO, 2020 NIHR, 2021 2020 2020 2020 Horby, 2020, Dexamethasone in hospitalized patients with covid-19 - preliminary report, N Engl J Med, 384, 693 2020 Águas, 2020, Analysis: the potential health and economic impact of dexamethasone treatment for patients with COVID-19, medRxiv, 2020 2020 Gordon, 2021, Interleukin-6 receptor antagonists in critically ill patients with covid-19 – preliminary report, NEJM 2021 2021 2020, RECOVERY. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet, 396, 1345, 10.1016/S0140-6736(20)32013-4 2021, Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet, 397, 605, 10.1016/S0140-6736(21)00149-5 Kelland, 2021 2021 University of Oxford, 2021 Agarwal, 2020, Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial), BMJ, 371, m3939, 10.1136/bmj.m3939 Libster, 2021, Early high-titer plasma therapy to prevent severe covid-19 in older adults, N Engl J Med, 384, 610, 10.1056/NEJMoa2033700 Beigel, 2020, Remdesivir for the treatment of covid-19 - final report, N Engl J Med, 383, 1813, 10.1056/NEJMoa2007764 Hsu, 2020, Covid-19: what now for remdesivir?, BMJ, 371, m4457, 10.1136/bmj.m4457 Pan, 2021, Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results, NEJM, 384, 497, 10.1056/NEJMoa2023184 WHO, 2020 Ramírez, 2021, Is ivermectin ready to be part of a public health policy for COVID-19 prophylaxis?, EClinicalMedicine, 32, 10.1016/j.eclinm.2021.100744 Chaccour, 2021, The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial, EClinicalMedicine, 32, 10.1016/j.eclinm.2020.100720 Jolliffe, 2021, Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of aggregate data from randomised controlled trials, Lancet Diabetes Endocrinology, 9, 276, 10.1016/S2213-8587(21)00051-6 Zemb, 2020, Vitamin D deficiency and the COVID-19 pandemic, J. Glob. Antimicrob. Resist., 22, 133, 10.1016/j.jgar.2020.05.006 Meltzer, 2020, Association of vitamin D status and other clinical characteristics with COVID-19 test results, JAMA Netw open, 3, 10.1001/jamanetworkopen.2020.19722 Kaufman, 2020, SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels, PloS One, 15, 10.1371/journal.pone.0239252 Entrenas Castillo, 2020, Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study, J Steroid Biochem Mol Biol, 203, 10.1016/j.jsbmb.2020.105751 Nogues, 2021, Calcifediol treatment and COVID-19-related outcomes., Preprints Lancet Haug, 2020 Martineau, 2020, Vitamin D for COVID-19: a case to answer?, Lancet Diab Endocrinol, 8, 735, 10.1016/S2213-8587(20)30268-0 2020